Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
The results of this trial support the hypothesis that memantine treatment leads to functional improvement and reduces care dependence in severely demented patients.
-
These results confirm the efficacy and safety of tacrine in some patients with Alzheimer's disease.
-
Huntington's disease patients had a lower prevalence of hypertension compared with age-matched gene-negative controls.
-
The average age in our 2 groups was 81.1 years, and 61.4% of our population was female.
-
Currently, five pharmacotherapeutic options are available to treat Alzheimer's disease: memantine; the three cholinesterase inhibitors donepezil, galantamine, and rivastigmine; and combination treatments with memantine and one cholinesterase inhibitor.
-
Alzheimer's disease (AD) results in progressively worsening cognitive decline, leading to loss of functional ability, behavior/mood disturbances, institutionalization, and death.
-
The Integrated Alzheimer's Disease (AD) Rating Scale (iADRS) is a composite tool that combines scores from the AD Assessment Scale-Cognitive subscale (ADAS-Cog) and the AD Cooperative Study - instrumental Activities of Daily Living (ADCS-iADL).
-
The evidence to support a specific time frame for discontinuation of Alzheimer's disease treatment is limited.
-
68/100
Currently available data indicate superior therapeutic effects of combination treatment for Alzheimer dementia with memantine and acetylcholine esterase inhibitors in certain clinical contexts.
-
In a double-blind trial, 12 patients with probable Alzheimer's disease were treated for 6 weeks with placebo and 6 weeks with monosialoganglioside (GM1) (100 mg/day i.m.), which potentiates the actions of nerve growth factor.
-
Aβ plaques removal in the brain due to amyloid therapy is strongly correlated with a better clinical response in patients with early Alzheimer's disease and a higher ARIA-E rate for the treatment groups and clinical trials in this meta-analysis.
-
67/100
Racial/ethnic groups differed in sources of recruitment, reasons for screen failure, and overall probability of eligibility in a preclinical AD trial.
-
Pioglitazone is a time- and dose-dependent protective factor against dementia in patients with diabetes.
-
Our results support an association between the use of ADT in the treatment of prostate cancer and an increased risk of Alzheimer's disease in a general population cohort.
-
Alzheimer's disease is a neurological disorder that results in cognitive and behavioral impairment.
-
Larger and better-designed studies are needed to draw unequivocal conclusions about the effect of statins on cognition.
-
In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months.
-
In covariate-adjusted intent-to-treat analyses, haloperidol was associated with the highest mortality rates (relative risk=1.54, 95% confidence interval [CI]=1.38-1.73) followed by risperidone (reference), olanzapine (relative risk=0.99, 95% CI=0.89-1.10), valproic acid and its derivatives (relative risk=0.91, 95% CI=0.78-1.06), and quetiapine (relative risk=0.73, 95% CI=0.67-0.80).
-
Because of flawed methods and small clinical benefits, the scientific basis for recommendations of cholinesterase inhibitors for the treatment of Alzheimer's disease is questionable.
-
Brief Report15 September 1991Postmenopausal Estrogen and Prevention BiasElizabeth Barrett-Connor, MDElizabeth Barrett-Connor, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-115-6-455 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn the last decade many investigators reported that postmenopausal women taking estrogen were at reduced risk for cardiovascular disease compared with women not taking estrogen (1).
-
ARIA-E incidence was 2.0% in non-carriers and 6.2% in εε4/εε4 homozygotes (εε4/εε4-versus-non-carrier OR 3.25, versus 8.49 in Clarity AD and 8.32 in Japan post-marketing surveillance).
-
ARIA were infrequent. In donanemab-treated patients, mildly symptomatic ARIA-E occurred in 10% (2/20) and asymptomatic ARIA-H in 15% (3/20).
-
BackgroundAlzheimer's disease (AD) is a growing neurodegenerative disorder causing cognitive decline, memory loss, and functional impairment.
-
The enrolled population of 84 subjects (31 homozygotes and 53 heterozygotes) was 52% females, mean age 69 years, MMSE 25.7 [70% mild cognitive impairment (MCI), 30% mild AD] with 55% on cholinesterase inhibitors.
-
In terms of efficacy, the review showed a statistically, but not clinically significant, improvement in favor of immunotherapy versus placebo.
From across this topic
10 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights
- Drug repositioning in Alzheimer's disease
- Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease
- Alzheimer's Disease: Treatment Challenges for the Future
- Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients
- Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center
- Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study
- Causal effect of conventional anti-dementia drugs on economic burden: an orthogonal double/debiased machine learning approach
- The cholinergic hypothesis of Alzheimer's disease: a review of progress
- [Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)]